Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 24;9(2):24.
doi: 10.3390/proteomes9020024.

A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation

Affiliations

A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation

Joel Ricky Steele et al. Proteomes. .

Abstract

Proteinopathies are protein misfolding diseases that have an underlying factor that affects the conformation of proteoforms. A factor hypothesised to play a role in these diseases is the incorporation of non-protein amino acids into proteins, with a key example being the therapeutic drug levodopa. The presence of levodopa as a protein constituent has been explored in several studies, but it has not been examined in a global proteomic manner. This paper provides a proof-of-concept method for enzymatically creating levodopa-containing proteins using the enzyme tyrosinase and provides spectral evidence of in vitro incorporation in addition to the induction of the unfolded protein response due to levodopa.

Keywords: L-DOPA; Levodopa; PTM; misincorporation; post-translational modifications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structural forms of phenylalanine, para-tyrosine, meta-tyrosine, ortho-tyrosine, and L-DOPA. Hydroxyl radical attack on the phenyl ring of phenylalanine residues can form isomers of tyrosine, the canonical form being para-tyrosine, but can also form meta-tyrosine and ortho-tyrosine; hydroxyl attack of tyrosine can also form L-DOPA.
Figure 2
Figure 2
Spectral evidence of a positive control for PB-DOPA. (A) The native peptide sequence. (B) Addition of oxygen to tyrosine indicated by the increase in peptide mass and altered masses of the b8 and y10 ions.
Figure 3
Figure 3
The overall oxidation profile of untreated, DOPA-treated and converted SH-SY5Y proteomes. The oxidation profile of methionine, tyrosine (L-DOPA), and phenylalanine is shown for each treatment group. The level of oxidation is presented as a percentage of the total number of identified peptides containing M, Y or F (top) and individual residues (bottom). The three biological control samples were pooled for the tyrosinase conversion, using tyrosinase to peptide digest ratios of 10:1, 2:1, and 1:1. Regardless of residue or peptide sequence, the percentage of oxidation follows a similar pattern for each sample. Error bars represent the standard error of the mean (SEM).
Figure 4
Figure 4
The ratio of total ion intensities compared to the control. Error bars represent the SEM.
Figure 5
Figure 5
Volcano plot of proteins from label-free quantitative analysis. Coloured proteins have p-value <0.05 and a log2 fold change of ≥1. Blue proteins are up in treatment, and red proteins are down.

Similar articles

Cited by

References

    1. Rascol O., Payoux P., Ory F., Ferreira J.J., Brefel-Courbon C., Montastruc J.-L. Limitations of current Parkinson’s disease therapy. Ann. Neurol. 2003;53:S3–S12. doi: 10.1002/ana.10513. - DOI - PubMed
    1. Parkkinen L., O’Sullivan S.S., Kuoppamäki M., Collins C., Kallis C., Holton J.L., Williams D.R., Revesz T., Lees A.J. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology. 2011;77:1420–1426. doi: 10.1212/WNL.0b013e318232ab4c. - DOI - PubMed
    1. Alexander T., Sortwell C.E., Sladek C.D., Roth R.H., Steece-Collier K. Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Transplant. 1997;6:309–315. doi: 10.1177/096368979700600313. - DOI - PubMed
    1. Asanuma M., Miyazaki I., Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox. Res. 2003;5:165–176. doi: 10.1007/BF03033137. - DOI - PubMed
    1. Chan S.W., Dunlop R.A., Rowe A., Double K.L., Rodgers K.J. L-DOPA is incorporated into brain proteins of patients treated for Parkinson’s disease, inducing toxicity in human neuroblastoma cells in vitro. Exp. Neurol. 2012;238:29–37. doi: 10.1016/j.expneurol.2011.09.029. - DOI - PubMed